This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Roche (RHHBY) Announces Positive Data on Hemophilia A Drug
by Zacks Equity Research
Roche Holdings AG (RHHBY) announced positive data from the phase III study, HAVEN 1, on hemophilia A candidate emicizumab.
Alnylam (ALNY) Stock Down Despite Positive Hemophilia Data
by Zacks Equity Research
Alnylam Pharmaceuticals, Inc. (ALNY) and Sanofi's (SNY) specialty care global business unit, Genzyme, announced encouraging results from the ongoing phase II open-label extension (OLE) study.
Alnylam Commences Phase III Study for Hemophilia Candidate
by Zacks Equity Research
Alnylam Pharmaceuticals, Inc. (ALNY) and Sanofi's (SNY) announced that it has commenced phase III ATLAS study for its candidate fitusiran.
Prima Biomed's Intra-Tumor Study on Lead Candidate Approved
by Zacks Equity Research
Prima Biomed Ltd. (PBMD) announced that a new clinical study, INSIGHT, on its lead candidate IMP321 has received regulatory approval for initiation
DBV Technologies (DBVT) Worth a Look: Stock Up 5.7%
by Zacks Equity Research
DBV Technologies S.A. (DBVT) was a big mover last session, as the company saw its shares rise nearly 6% on the day.
Endo (ENDP) to Remove Opioid Pain Drug Opana ER from Market
by Zacks Equity Research
Endo International plc (ENDP) recently announced that it will withdraw opioid pain medication Opana ER (oxymorphone hydrochloride extended release) from the market following FDA's request in June.
Shire Completes NDA Filing for Hemophilia Drug with FDA
by Zacks Equity Research
Shire plc (SHPG) recently announced that it has filed an investigational new drug (IND) application with the FDA, seeking approval for its recombinant factor VIII (FVIII) gene therapy candidate, SHP654, for the treatment of patients with Hemophilia A.
Alexion Reportedly Being Investigated by HHS, Shares Slip
by Zacks Equity Research
Shares of Alexion Pharmaceuticals, Inc. (ALXN) were down more than 3% on Thursday after a Bloomberg report stated that it is under investigation by the U.S. Department of Health and Human Services' (HHS) Office of Inspector General (OIG).
ProQR's Usher Syndrome Candidate Gets Orphan Drug Status
by Zacks Equity Research
ProQR Therapeutics N.V. (PRQR) announced that its key pipeline candidate, QRX-411, has been granted orphan drug designation by the FDA and European Medicines Agency (EMA) for the treatment of retinitis pigmentosa.
Blueprint Medicines (BPMC) Shows Strength: Stock Adds 9.6% in Session
by Zacks Equity Research
Blueprint Medicines Corporation (BPMC) was a big mover last session, as the company saw its shares rise nearly 10% on the day.
Abeona Therapeutics (ABEO) Catches Eye: Stock Jumps 10.6%
by Zacks Equity Research
Abeona Therapeutics Inc. (ABEO) moved big last session, as the company saw its shares rise over 10% on the day.
Sucampo (SCMP) Remains Focused on Amitza Label Expansion
by Zacks Equity Research
We issued an updated report on Sucampo Pharmaceuticals, Inc. (SCMP) on July 4.
AMAG Pharmaceuticals Focuses on Product Development & Buyouts
by Zacks Equity Research
We issued an updated report on AMAG Pharmaceuticals, Inc. (AMAG) on Jul 4.
BeiGene (BGNE) Surges: Stock Moves 20.8% Higher
by Zacks Equity Research
BeiGene (BGNE) was a big mover last session, as the company saw its shares rise almost 21% on Monday amid huge volumes.
Bayer Starts Phase III Study for Uterine Fibroids' Candidate
by Zacks Equity Research
Bayer Aktiengesellschaft (BAYRY) announced that it has enrolled the first patient in a phase III study ASTEROID which will evaluate vilaprisan in women suffering from uterine fibroids.
Marinus' (MRNS) Ganaxolone Gets Orphan Drug Status in US
by Zacks Equity Research
Marinus Pharmaceuticals, Inc. (MRNS) announced that the FDA has granted orphan drug designation to its key candidate, ganaxolone, for the treatment of adult and pediatric patients with CDKL5 disorder.
Esperion's Combo Cholesterol Candidate Enters Phase III
by Zacks Equity Research
Esperion Therapeutics, Inc. (ESPR) received positive feedback from the FDA for initiation of a phase III bridging study, evaluating the combination of bempedoic acid (180 mg) and Zetia (10 mg) for an LDL-C lowering indication.
5 Biomedical Stocks That Are Expected To Surge
by Jeffrey Hymen
With the promise of regulatory reform on the horizon, investors have been excited about the biomedical space throughout the year. If you want to add some to your portfolio, check out these 5 biomedical stocks that are primed to skyrocket here.
Surging Earnings Estimates Signal Good News for Enzo Biochem (ENZ)
by Zacks Equity Research
Enzo Biochem (ENZ) is seeing positive earnings estimate revisions suggesting that it could be a solid choice for investors.
Enzo Biochem (ENZ) Shares March Higher, Can It Continue?
by Zacks Equity Research
Enzo Biochem, Inc. (ENZ) has been on the move lately as the stock has risen by 19.1% in the past four weeks, and it is currently trading well above its 20-Day SMA
Looking for a Top Momentum Stock? 3 Reasons Why Enzo Biochem (ENZ) is a Great Choice
by Zacks Equity Research
Enzo Biochem (ENZ) is a solid momentum stock that has a favorable Zacks Rank and is seeing solid earnings estimate revisions.
Enzo Biochem (ENZ) Looks Good: Stock Jumps 13.3% in Session
by Zacks Equity Research
Enzo Biochem, Inc. (ENZ) shares rose above 13% in the last trading session.
Merrimack (MACK) Q1 Loss Wider than Expected, Sells Onivyde
by Zacks Equity Research
Merrimack Pharmaceuticals, Inc. (MACK) reported a loss of 22 cents per share in the first quarter of 2017, wider than the Zacks Consensus Estimate of a loss of 7 cents. The company had reported a loss of 32 cents in the year-ago quarter.
Orexigen Posts Wider-than-Expected Loss in Q1, Sales Up Y/Y
by Zacks Equity Research
Orexigen Therapeutics, Inc.'s (OREX) loss of $4.67 per share in the first quarter of 2017 was significantly wider than the Zacks Consensus Estimate of a loss of $2.60 and the year-ago loss of $1.54.
Alnylam (ALNY) Q1 Loss Wider than Expected, Revenues Up Y/Y
by Zacks Equity Research
Alnylam Pharmaceuticals, Inc. (ALNY) reported a loss of $1.25 per share in the first quarter of 2017, wider than the Zacks Consensus Estimate of a loss of $1.22 and the year-ago loss of $1.21.